Table 5.

Marketed PDE inhibitors in cardiovascular diseases

Drug Name	Trade Name	PDE Selectivity	Indications
Vinpocetine	Cavinton	PDE1	Cerebral vascular disorders
Cilostazol	Pletal	PDE3A, PDE4A	Intermittent claudication
Milrinone	Primacor	PDE3A, PDE4A	Congestive HF
Amrinone	Inocor	PDE3A, PDE4	Congestive HF
Enoximone	Perfan	PDE3A	Congestive HF
Olprinone	Coretec	PDE3	HF
Pimobendan	Acardi	PDE3	HF
Sildenafil	Viagra	PDE5	Erectile dysfunctionPulmonary arterial hypertension
Tadalafil	Cialis	PDE5	Erectile dysfunctionPulmonary arterial hypertension
Udenafil	Zydena	PDE5	Pulmonary arterial hypertension
Vardenafil	Levitra	PDE5	Erectile dysfunction
Avanafil	Stendra	PDE5	Erectile dysfunction
Lodenafil	Helleva	PDE5	Erectile dysfunction
Mirodenafil	Mvix	PDE5	Erectile dysfunction
Pentoxifylline	Trental	PDE4, PDE5, adenosine 2 receptors	Intermittent claudication
Cicletanine	Tenstaten	cGMP-PDE specific	Hypertension
Papaverine	Pavabid	PDE10A	Vascular spasm

FDA, food and drug administration; HF, heart failure; PDE, phosphodiesterase.